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ABSTRACT
Treatment of rheumatoid arthritis (RA) may differ among 
rheumatologists and currently, clear and consensual 
international recommendations on RA treatment 
are not available. In this paper recommendations for 
the treatment of RA with synthetic and biological 
disease-modifying antirheumatic drugs (DMARDs) 
and glucocorticoids (GCs) that also account for 
strategic algorithms and deal with economic aspects, 
are described. The recommendations are based on 
evidence from ﬁ  ve systematic literature reviews 
(SLRs) performed for synthetic DMARDs, biological 
DMARDs, GCs, treatment strategies and economic 
issues. The SLR-derived evidence was discussed and 
summarised as an expert opinion in the course of a 
Delphi-like process. Levels of evidence, strength of 
recommendations and levels of agreement were derived. 
Fifteen recommendations were developed covering 
an area from general aspects such as remission/low 
disease activity as treatment aim via the preference 
for methotrexate monotherapy with or without GCs 
vis-à-vis combination of synthetic DMARDs to the use of 
biological agents mainly in patients for whom synthetic 
DMARDs and tumour necrosis factor inhibitors had failed. 
Cost effectiveness of the treatments was additionally 
examined. These recommendations are intended to 
inform rheumatologists, patients and other stakeholders 
about a European consensus on the management of RA 
with DMARDs and GCs as well as strategies to reach 
optimal outcomes of RA, based on evidence and expert 
opinion.
INTRODUCTION
The management of rheumatoid arthritis (RA) 
rests on several principles. Drug treatment, which 
comprises disease-modifying antirheumatic drugs 
(DMARDs), but also non-steroidal anti-inﬂ  am-
matory drugs and glucocorticoids (GCs), as well 
as non-pharmacological measures, such as physi-
cal, occupational and psychological therapeutic 
approaches, together may lead to therapeutic suc-
cess. However, the mainstay of RA treatment is the 
application of DMARDs. It is DMARD treatment, 
especially, which has undergone dramatic changes 
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during the past decade, providing previously unfore-
seen therapeutic dimensions. New and highly 
effective DMARDs have continued to emerge 
until the most recent years—in particular, biologi-
cal agents which target tumour necrosis factor, the 
interleukin 1 (IL-1) receptor, the IL-6 receptor, B 
lymphocytes and T-cell costimulation.1 In addition, 
a chemical DMARD, leﬂ   unomide, has become 
available and compounds which have been in use 
for many decades, such as methotrexate (MTX) 
and sulfasalazine (SSZ), as well as GCs, have been 
re-examined in order to achieve better efﬁ  cacy. 
For example, the use of high dose MTX2 and the 
disease-modifying effects of GCs, especially when 
combined with traditional DMARDs,3–7 are now 
well established. Furthermore, treatment strategies 
have changed during this period, initially by calling 
for early referral and early institution of DMARD 
treatment on the basis of respective evidence of 
clinical efﬁ  cacy,8–10 and later by showing that tight 
control using composite measures of disease activ-
ity and appropriate switching of drug treatment are 
highly efﬁ  cacious approaches.11–14
While all these data of clinical and observational 
trials on drugs and strategies have been highly 
enlightening, patients and rheumatologists are cur-
rently overwhelmed by this information which 
does not always allow one to decide easily and 
conclusively which path to follow when initiating 
or changing therapeutic strategies in patients with 
RA. Indeed, some inconsistencies in therapeutic 
targets and strategies among rheumatologists have 
been recognised in a survey performed at a recent 
annual European Congress of Rheumatology.15 
These inconsistencies may be partly based on 
differences in attitudes among doctors caring for 
patients with RA, settings (academic centres vs pri-
vate practice), patient preferences and reimburse-
ment policies. Information on the current state of 
evidence for the efﬁ  cacy of different agents or ther-
apeutic strategies may also not always be regarded 
as sufﬁ  ciently complete or available.
Along these lines, the European League Against 
Rheumatism (EULAR) has recently formulated 
major objectives, which among other aspects 
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specify that “by 2012, EULAR will have provided standards of 
care and foster access to optimal care of people with musculo-
skeletal conditions in Europe”.16 Since disease modiﬁ  cation con-
stitutes the most important therapeutic intervention in RA, it 
was the objective of this EULAR Task Force to ﬁ  nd a consensus 
on recommendations for the management of RA with synthetic 
and biological DMARDs.
METHODS
The task force aimed at aggregating available information on 
disease modiﬁ   cation in RA into practical recommendations. 
The basis of the activities of the task force were the EULAR 
standardised operating procedures for the development of rec-
ommendations,17 which suggest the institution of an expert 
committee in charge of consensus ﬁ  nding on the basis of evi-
dence provided by a systematic literature review (SLR) and 
expert opinion. The task of developing management recom-
mendations for RA was regarded as large and therefore war-
ranted division of the topic into ﬁ  ve main areas: (a) synthetic 
DMARDs as monotherapy or in combination without GCs; (b) 
GCs alone and in combination with synthetic DMARD(s); (c) 
biological DMARDs; (d) treatment strategies; (e) economic 
issues. The last aspect was deemed important to understand 
the cost implications of treating RA by retrieving the exist-
ing evidence; the fourth area was intended to look at the best 
approaches to attain the therapeutic goals, deﬁ   ne the term 
‘strategy’ as a long-term plan of action to achieve that goal; and, 
most importantly, the ﬁ  rst three areas were related to the evi-
dence available for the efﬁ  cacy, safety and monitoring of cur-
rently employed drugs.
The recommendations will reﬂ  ect the balance of efﬁ  cacy and 
safety and will not deal in detail with the toxicity of DMARDs. 
The most important pieces of information in this regard are 
provided in separate publications on the SLRs,18–22 which 
indeed are part and parcel of these recommendations, since 
they provide their bases. Thus, the recommendations shown 
here will   primarily deal with agents whose toxicity appears 
to be manageable, assuming that users are either aware of the 
respective risks or will adhere to the information provided in 
the package inserts. Also, where toxicity appears to be a major 
concern, a general warning will be included in the respective 
recommendation.
The expert committee comprised 25 rheumatologists, two 
patients, one infectious disease specialist, one health economist 
and ﬁ  ve fellows. The members of this task force came from 12 
European countries and from the USA. The expert commit-
tee was divided into ﬁ  ve subgroups; each consisted of ﬁ  ve to 
seven members including one fellow and dealt with one of the 
above topics. At the ﬁ  rst meeting, these subgroups prioritised 
the research questions, deﬁ  ned the appropriate search terms and 
reported to the full committee, which took the ﬁ  nal decisions by 
consensus.
Subsequently, the fellows, with the help of their mentors, 
performed the respective SLR searching PubMed, Embase, 
Medline and the Cochrane library and also recent abstracts, up 
to the middle of 2009. The SLRs included meta-analyses, sys-
tematic reviews, randomised controlled trials (RCTs), non-RCTs 
and observational studies, including data from registries. The 
  individual research questions, in particular on the efﬁ  cacy and 
toxicity of the agents under investigation, were examined by 
looking at the population of adult patients with RA, the type of 
agent, the control used for comparison and the outcome. If pos-
sible, outcome was quantiﬁ  ed using effect sizes, which are unit-
less and therefore allow for the analysis of efﬁ  cacy irrespective of 
the measures evaluated in individual clinical trials; these data will 
be solely discussed in the reports on the SLRs. Categorisations 
of evidence and strength of recommendation were determined 
according to the standards of the Oxford Centre for Evidence 
Based Medicine.23
At the second task force meeting, the fellows presented the 
results of the SLR in an aggregated form to the subgroups. The 
members of the subgroups debated and evaluated the evidence 
presented and formulated preliminary sets of recommendations. 
These proposals were reported to the entire task force, which 
discussed the suggestions on the recommendations in detail, 
amended them as deemed appropriate in the course of the con-
sensus ﬁ  nding and took the ﬁ  nal decisions. An ultimate round of 
reﬁ  nement of the wording was done via electronic communica-
tion, by which also an anonymous voting on the level of agree-
ment was performed. In addition, respondents were asked to 
indicate which of the statements were in line with their current 
treatment practice and, if not, whether they would change that 
practice. The task force started its work in December 2008 and 
ﬁ  nalised it in June 2009.
RESULTS
Overarching principles
Before dealing with the actual treatment recommendations, the 
task force discussed several principles that were deemed impor-
tant to be conveyed to those with RA or involved with the man-
agement of RA. These principles for the care of patients with RA 
are of such generic nature that they were felt to be ‘overarching’ 
(table 1). The task force decided unanimously on these three 
principles.
(A) Rheumatologists are the specialists who should primar-
ily care for patients with RA. This statement stems from 
the   evidence that patients with RA followed up by 
rheumatologists, in comparison with other doctors, 
are diagnosed earlier, receive DMARD treatment more 
frequently and have better outcomes in all major char-
acteristics of RA, in particular joint damage and physical 
function.24–28 Rheumatologists check the disease activity 
of their patients with RA with appropriate instruments 
and are well aware of the indications, contraindications 
and adverse effects of DMARDs; this has become of 
particular importance with the advent of modern treat-
ments and strategies. Therefore, patients with inﬂ  amma-
tory arthritis, in general, and suspected RA, in particular, 
should be referred to rheumatologists as early as pos-
sible, since a delay in such a referral is one of the most 
daunting causes of tardy institution of effective treat-
ment.9 29 However, the task force intentionally added the 
term ‘primarily’ to this statement, since the management 
of patients with RA should be shared with primary care 
doctors and other health professionals in a multidisci-
plinary approach. Also, in countries lacking sufﬁ  cient 
numbers of rheumatologists, this task may have to be 
taken over by other doctors with experience in caring for 
patients with RA.
(B) Treatment of patients with RA should aim at the best care and 
must be based on a shared decision between the patient and the 
rheumatologist. Two themes govern the contents of this 
principle—ﬁ  rst, the term ‘best care’, which the task force 
felt to be conveyed by the subsequent recommendations, 
and second, the phrase ‘shared decision’ with the patient, 
which refers to the need to discuss treatment aims, 
management plans and reasons for the recommended 
approaches with the patient.
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(C) RA is expensive in regards to medical costs and productiv-
ity costs, both of which should be considered by the treating 
rheumatologist. The expert committee wished to encapsu-
late that the direct and indirect costs of RA, especially if 
insufﬁ  ciently treated, are very high.28 30–33 Modern treat-
ments, particularly biological agents, are expensive,30 34 35 
but may enable lowering of short- and long-term indirect 
costs of disease—an actuality that should be kept in 
mind for individual treatment approaches as well as 
reimbursement considerations. This underlying principle 
also reinforces the decision to evaluate economic aspects 
in relation to the individual recommendations to exam-
ine the cost effectiveness of RA treatment.
Recommendations
In each subgroup, the members discussed the evidence provided 
by the fellows in their SLRs in detail and agreed on ﬁ  ve to eight 
recommendations for the respective topic. These preliminary 
statements on the management of RA with synthetic DMARDs, 
GCs and biological agents, as well as on treatment strategies and 
economic aspects, were subsequently reviewed intensively by 
the whole task force, synthesised and voted upon. This process 
led to 15 recommendations on drug management and treatment 
strategies. Each of these 15 recommendations was then sub-
jected to an economic valuation in accordance with the results 
obtained by the economics subgroup of the task force.
The 15 recommendations (detailed in table 1) are presented in 
the text below in an abbreviated version. The levels of evidence 
and strengths of recommendation for each recommendation are 
then shown in table 2 and the economic valuation in table 3. 
The 15 recommendations are ordered by a logical sequence or 
procedural and chronological hierarchy rather than by any major 
weight of importance, with the exception of the ﬁ  rst two points 
which constitute the foundation of all subsequent items. They 
also serve as basis for the algorithm provided in ﬁ  gure 1.
(1) Synthetic DMARDs early— The task force was unani-
mous in its view that in the vast majority of patients 
with RA the ﬁ  rst treatment approach should include 
synthetic DMARDs, since a signiﬁ  cant proportion of 
patients can attain a state of very low disease activity or 
remission36–39; the types of DMARD with evidence of 
efﬁ  cacy will be discussed in items 3–6. Moreover, since 
any delay in the start of DMARD treatment in patients 
with RA may lead to a worse outcome in comparison 
with an early start of treatment,8 10 40 DMARD treatment 
should be started as soon as a diagnosis of RA has been 
made. However, a diagnosis of RA in its earliest stage is 
not always easy and a suspected diagnosis of RA may 
be sufﬁ  cient to initiate DMARD treatment. Importantly, 
American College of Rheumatology (ACR) and EULAR 
have collaboratively developed new criteria that are 
pertinent for this early phase of the disease.41
(2) Treatment targeting remission or low disease activity—
Undoubtedly, attaining a state of remission or low 
disease activity leads to better structural and functional 
outcomes than allowing residual disease activity11 42–46 
and the earlier such a state is achieved the better.43 47 
Thus, remission is the primary therapeutic aim, espe-
cially in early RA, though low disease activity may be 
an appropriate alternative, especially in patients with 
longstanding RA, as was also concluded by an expert 
committee recently engaged in deﬁ  ning a treatment 
target for RA.48 Strategic trials have shown that aiming at 
Table 1  Recommendations for the management of rheumatoid arthritis 
with non-biological and biological disease-modifying antirheumatic 
drugs.
Overarching principles
A Rheumatologists are the specialists who should primarily 
care for patients with RA
B Treatment of patients with RA should aim at the best care 
and must be based on a shared decision between the 
patient and the rheumatologist
C RA is expensive in regards to medical costs and productivity 
costs, both of which should be considered by the treating 
rheumatologist.
Final set of 15 recommendations for the management of RA
1 Treatment with synthetic DMARDs should be started as 
soon as the diagnosis of RA is made
2 Treatment should be aimed at reaching a target of 
remission or low disease activity as soon as possible in 
every patient; as long as the target has not been reached, 
treatment should be adjusted by frequent (every 1–3 
months) and strict monitoring
3 MTX should be part of the ﬁ  rst treatment strategy in 
patients with active RA
4 When MTX contraindications (or intolerance) are present, 
the following DMARDs should be considered as part of the 
(ﬁ  rst) treatment strategy: leﬂ  unomide, SSZ or injectable 
gold
5 In DMARD naïve patients, irrespective of the addition 
of GCs, synthetic DMARD monotherapy rather than 
combination therapy of synthetic DMARDs may be 
applied
6 GCs added at low to moderately high doses to synthetic 
DMARD monotherapy (or combinations of synthetic 
DMARDs) provide benefit as initial short-term treatment, 
but should be tapered as rapidly as clinically feasible
7 If the treatment target is not achieved with the ﬁ  rst 
DMARD strategy, addition of a biological DMARD should be 
considered when poor prognostic factors are present; in the 
absence of poor prognostic factors, switching to another 
synthetic DMARD strategy should be considered
8 In patients responding insufﬁ  ciently to MTX and/or 
other synthetic DMARDs with or without GCs, biological 
DMARDs should be started*; current practice would be to 
start a TNF inhibitor (adalimumab, certolizumab, etanercept, 
golimumab, inﬂ  iximab)† which should be combined with 
MTX*
9 Patients with RA for whom a ﬁ  rst TNF inhibitor has failed, 
should receive another TNF inhibitor, abatacept, rituximab 
or tocilizumab
10 In cases of refractory severe RA or contraindications to 
biological agents or the previously mentioned synthetic 
DMARDs, the following synthetic DMARDs might be also 
considered, as monotherapy or in combination with some 
of the above: azathioprine, ciclosporin A (or exceptionally, 
cyclophosphamide)
11 Intensive medication strategies should be considered 
in every patient, although patients with poor prognostic 
factors have more to gain
12 If a patient is in persistent remission, after having tapered 
GCs, one can consider tapering biological DMARDs‡, 
especially if this treatment is combined with a synthetic 
DMARD
13 In cases of sustained long-term remission, cautious titration 
of synthetic DMARD dose could be considered, as a shared 
decision between patient and doctor
14 DMARD naïve patients with poor prognostic markers might 
be considered for combination therapy of MTX plus a 
biological agent
15 When adjusting treatment, factors apart from disease activity, 
such as progression of structural damage, comorbidities and 
safety concerns should be taken into account
Symbols *, † and ‡ refer to levels of evidence provided in table 2.
DMARD, disease-modifying antirheumatic drug; GCs, glucocorticoids; MTX, 
methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor.
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low disease activity or remission by adjusting treatment 
every 1–3 months in conjunction with strict monitor-
ing is associated with a better clinical, radiographic and 
functional outcome than with an unstructured follow-
up.11 13 49 Thus, the treatment target should preferably 
be reached, or almost reached, within 3 months and 
deﬁ  nitely attained by a maximum of 6 months; while 
this time frame was not directly tested in comparative 
trials, this expert opinion is based on the use of a 1–3 
months’ period for switching treatments in strategy 
trials11–14 and on data showing that disease activity 
states at 3–6 months after treatment initiation predict 
outcome at later time points.50 Within this time frame of 
3–6 months patients should be followed up meticulously 
(every month if necessary) and existing treatment should 
be intensiﬁ  ed or ultimately changed for another.48 In line 
with these recommendations, monitoring should be reg-
ularly performed. While several different measures have 
been employed in various strategy trials,21 expert opinion 
has recently suggested using composite measures of dis-
ease activity which include joint counts.48 Valid measures 
for this purpose have been recently reviewed and include 
the Disease Activity Score (DAS), 28-joint count DAS 
(DAS28), Simpliﬁ  ed Disease Activity Index and Clinical 
Disease Activity Index.51
(3) MTX as initial choice—MTX is a highly effective drug for 
disease modiﬁ  cation in RA,52 and more recent insights 
suggest that MTX at higher weekly doses (20–30 mg) 
is more effective than MTX at lower weekly doses 
(7.5–15 mg).2 53 MTX is considered the anchor drug in 
RA,54 both on the basis of its efﬁ  cacy as monotherapy 
and on the basis of its ability to increase the efﬁ  cacy of 
biological DMARDs when used in combination,55–59 as 
well as the beneﬁ  cial long-term safety proﬁ  le.60 MTX is 
effective in DMARD naïve patients with early RA,13 49 
56 61 and its clinical efﬁ  cacy has neither been surpassed 
by other synthetic DMARDs nor consistently by tumour 
necrosis factor (TNF) inhibitor monotherapy.37 55 56 62 For 
these reasons the task force considered that MTX should 
be instituted at the earliest time point in patients with 
RA. This statement comprises three items in addition 
to the recommendation for using MTX: ﬁ  rst, it uses the 
wording ‘part of the ﬁ  rst treatment strategy’, implying 
that MTX may have to be combined with other agents 
(see below); second, it refers to ‘active RA’, implying 
that patients with low disease activity may not necessar-
ily need treatment with MTX; and third, the statement 
indicates implicitly that a strategy using MTX should 
be applied also to patients with active RA who have 
previously not received MTX, but only other synthetic 
DMARDs. Obviously this recommendation does not 
pertain to patients for whom a contraindication for MTX 
use is present (see below).
(4) Leﬂ  unomide, SSZ or injectable gold—There is currently 
insufﬁ  cient evidence that leﬂ  unomide, SSZ or intra-
muscular gold salts are inferior to MTX.37 38 62–64 
Nevertheless, because of the wealth of efﬁ  cacy and 
safety data available for MTX, the three mentioned 
DMARDs should be used instead of MTX as ﬁ  rst 
DMARD treatments mainly if there are contraindica-
tions to (or intolerance of) MTX. In analogy with the 
previous paragraph, these MTX alternatives should also 
be considered as a part of a treatment strategy. The 
rather prominent place of parenteral gold salts has been 
the subject of intensive debate, but can be justiﬁ  ed by 
the currently available high-level evidence,63 65 66 and 
this decision was ultimately backed by the majority 
of the task force. In addition to the drugs mentioned 
above, antimalarial drugs (hydroxychloroquine and 
chloroquine) are also used in RA. They show some 
efﬁ  cacy as monotherapy with respect to signs and 
symptoms67 and are frequently used as part of combina-
tion therapies.42 68 69 It is, however, not clearly estab-
lished if antimalarial drugs confer additional efﬁ  cacy in 
combination therapy. In addition, antimalarial drugs do 
not inhibit structural damage sufﬁ  ciently, especially in 
comparison with other agents such as SSZ.70 Therefore 
they have not been mentioned more prominently in the 
recommendation statement. Nevertheless, on the basis 
of their clinical efﬁ  cacy as monotherapy they may have 
some value in patients with very mild disease who have 
contraindications to other compounds.
(5) Synthetic DMARD monotherapy or combination therapy—
Over the past two decades, combination therapy with 
various synthetic DMARDs has been suggested to 
convey superior efﬁ  cacy in comparison with monothera-
py.7 42 68 69 71 Results of clinical trials testing the addition 
of synthetic DMARDs to MTX in patients with residual 
disease activity despite MTX treatment have often been 
used to support the assumption of an added beneﬁ  t72 73; 
however, in these studies an appropriate control (switch) 
arm was lacking and the proportion of responders receiv-
ing combination therapy did not exceed the proportion 
of responders receiving the monotherapy components.74 
An important fact to consider to truly   appreciate the 
content of this recommendation, however, is that in 
most clinical trials comparing combination therapy with 
monotherapy head to head, GCs were either manda-
tory in the combination therapy arm or GC use was 
different between both arms, which probably explains 
the superiority of combination therapy.74 Several other 
trials suggest that in the absence of GCs neither a start 
with combinations of   synthetic DMARDs nor a step up 
Table 2  Level of evidence, grade of recommendation and level of 
agreement
Recommendation Level of evidence
Grade of 
recommendation Level of agreement
1 1a A 9.9±0.4
2 1b A 9.7±0.7
3 1a A 9.8±0.5
4 1a A 8.6±1.5
5 1a− A 8.5±2.0
6 1a− A 8.7±1.7
7 5 D 8.8±1.7
8 *1b
†4
*A
†C
9.3±1.5
9 1b A 9.5±0.9
10 1a- B 8.1±1.6
11 1b B 9.2±1.2
12 3b B 8.4±1.6
13 4 C 8.5±1.9
14 2b C 8.0±2.3
15 3b C 9.5±1.1
Symbols refer to the corresponding symbols in the recommendations presented in 
table 1 and show the respective evidence for those.
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combination therapy are better than monotherapies or 
switching DMARDs for the major outcomes.49 75–77 The 
SLR on this allowed a ﬁ  rm conclusion to be drawn.18 
Furthermore, in DMARD naïve patients the balance of 
efﬁ  cacy and toxicity favours MTX monotherapy versus 
combination therapy, while the evidence is inconclusive 
in DMARD inadequate responders.78 Therefore, the task 
force decided to use the word ‘may’ here. It is impor-
tant to keep in mind that if combination therapy with 
synthetic DMARDs does not allow the treatment target 
to be achieved, it is impossible to disentangle which of 
the agents was insufﬁ  ciently effective, precluding better 
usage of synthetic DMARDs. The statement contains yet 
another element—namely, the segment “irrespective of 
the addition of GCs”. The committee was unanimous in 
its opinion that the addition of GCs to either monother-
apy or combination therapy with DMARDs improves 
outcomes. However, studies allowing a direct compari-
son of GCs plus DMARD monotherapy versus GCs plus 
combination DMARDs have not been done.
(6) Glucocorticoids—GCs have been shown to have not only 
anti-inﬂ  ammatory but clearly also disease-modifying 
properties.5 79 80 The evidence that DMARD monother-
apy is as efﬁ  cacious as DMARD combination therapy 
suggests that the signiﬁ  cantly better outcomes of trials 
using combinations of synthetic DMARDs plus GCs 
versus DMARD monotherapy might be due to the GC 
component.7 12 42 This notion ﬁ  nds important support 
in studies which show that adding GCs to DMARD 
monotherapy3 4 is beneﬁ  cial. GC treatment has been 
added to DMARDs successfully at low doses (<10 mg/
day),3 4 42 but more rapid improvement may be achieved 
by addition of GCs at higher doses for the short term.7 
49 However, the added efﬁ  cacy of high-dose GCs has 
not yet been compared with that of low-dose GCs 
and, therefore, sufﬁ  cient evidence for this is lacking. 
Importantly, long-term use of GCs can lead to adverse 
events,81 but there may also be safety concerns in 
the intermediate term, although most studies on the 
toxicity of GCs are of low quality and short duration. 
Nevertheless, their toxicity, particularly in the intermedi-
ate to long term, should in the opinion of the task force 
not be disregarded and thus GCs should be used with 
caution and preferably for only short periods of time. 
Consequently, GCs should be tapered as rapidly as pos-
sible in accordance with the clinical situation. The safety 
of GCs was also an important aspect of the EULAR rec-
ommendations on the management of GC treatment.82
(7) Addition of a biological DMARD or switch to another synthetic 
DMARD—This statement introduces the importance of 
prognostic markers in treatment decisions in RA. Factors 
believed to predict bad outcome independently are (a) 
the presence of autoantibodies, that is, rheumatoid factor 
and/or anticitrullinated peptide antibodies, particularly 
at high levels; (b) high disease activity as measured by 
composite indices (DAS, DAS28, Simpliﬁ  ed Disease 
Activity Index and Clinical  Disease Activity Index), 
swollen joint counts or acute phase reactants (C reac-
tive protein, erythrocyte sedimentation rate); (c) early 
occurrence of erosions83–87; these factors have recently 
also been amalgamated into a risk model.88 The task 
force agreed that patients failing to reach the treatment 
target on an initial strategy with synthetic DMARDs, 
in whom poor prognostic markers as deﬁ  ned above are 
absent, could be switched to another synthetic DMARD 
strategy for 3–6 months before further decisions on the 
institution of a biological agent are taken; these other 
DMARDs have been mentioned in recommendation 4. 
However, patients for whom an initial DMARD failed 
and who have poor prognostic markers should have the 
opportunity to receive a biological DMARD in addition 
to their synthetic DMARD. Interestingly, closing a gap 
of information by using a control arm receiving active 
treatment, a recent study which was not part of the 
SLR reported that for patients with early RA who had 
failed to reach low disease activity after 3 months’ MTX 
monotherapy, the addition of a TNF inhibitor yielded 
signiﬁ  cantly better clinical outcomes than the addition of 
SSZ plus hydroxychloroquine.89 These data also corrobo-
rate the conclusions discussed in recommendations 5 and 
6—namely, that a combination of synthetic DMARDs 
in the absence of added GCs (even triple treatment of 
MTX, SSZ and hydroxychloroquine) has limited efﬁ  cacy 
and may not have higher efﬁ  cacy than if the patients had 
been switched to SSZ, as was shown in the BeSt trial.12 
This limited (but partly exhibited) efﬁ  cacy of such a syn-
thetic DMARD regimen also supports the expert opinion 
of switching patients for whom a ﬁ  rst DMARD strategy 
has failed and who do not have bad prognostic markers 
to another DMARD (or eventually DMARD combina-
tion). In contrast, for patients for whom initial MTX or 
other synthetic DMARDs (ideally with GCs) has failed 
and who have bad prognostic indicators a biological 
DMARD, in general, and a TNF inhibitor, in particular, 
should be employed. Importantly, however, no ran-
domised controlled or observational clinical trials to date 
have tested this approach of differential treatment based 
on prognostic factors. Therefore, this statement is at the 
level of an expert opinion, but is supported by various 
indirect evidence provided in the existing literature.
(8) Initiation of a TNF inhibitor—This expansion of statement 
No 7, which applies to patients followed according to 
that previous statement, emphasises that biological 
agents are effective if synthetic DMARDs have failed 
(level 1a, grade A) and that they should be combined 
with MTX (or other DMARDs), since this combination 
has greater efﬁ  cacy than monotherapy with most bio-
logical agents; this is well established for TNF inhibitors 
on the basis of respective comparative phase III trials55 
56 and for rituximab and tocilizumab on the basis of 
comparative phase II trials58 59 (level 1b, grade A). At the 
time of the SLR, the only biological agents licensed in 
Europe for treating patients with RA with active disease 
despite synthetic DMARD treatment were the TNF 
inhibitors and tocilizumab; rituximab and abatacept 
are currently licensed only for use after failure of TNF 
inhibitors. In the USA, though not currently in Europe, 
abatacept can also be used in these former patients; in 
light of more recent clinical trial data,90 91 abatacept and 
rituximab may receive similar approval as ﬁ  rst biologi-
cal agents by the European regulatory authorities in due 
course. It is noteworthy that some TNF inhibitors such 
as adalimumab and etanercept are licensed as mono-
therapy on the basis of their efﬁ  cacy in clinical trials, 
but the data on their clinical superiority compared with 
MTX monotherapy are partly mixed.55 56 92 Recent data 
suggest that monotherapy with tocilizumab is more 
effective than monotherapy with DMARDs such as 
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MTX93 94; however, this RCT did not include a third arm 
using the combination of both so that it is not clear to 
date whether in patients with early RA monotherapy 
with tocilizumab is similarly or less effective than com-
bination therapy with tocilizumab and MTX. Currently, 
the largest array of safety information is available for 
the TNF inhibitors owing to their use for more than one 
decade and the availability of large long-term registries. 
These compounds comprise adalimumab, etanercept 
and inﬂ  iximab, but certolizumab and golimumab have 
meanwhile also been approved. However, it should 
be borne in mind that this represents current expert 
opinion and may change over time, speciﬁ  cally with the 
recent approval of other biological agents as potential 
ﬁ  rst biological agent for DMARD inadequate respond-
ers—namely, tocilizumab in Europe and abatacept in 
the USA and other non-European countries. It should 
also be mentioned here that anakinra, the IL-1 receptor 
antagonist, while effective in individual patients with 
RA, did not show a high level of clinical efﬁ  cacy in clini-
cal trials95 96 and therefore has not been recommended 
as a major biological agent for use in RA.
(9) Abatacept, rituximab or tocilizumab—There is high-level 
evidence from one RCT each that abatacept, golimumab, 
rituximab and tocilizumab are effective in patients for 
whom TNF inhibitor therapy has failed97–100 (level 1b, 
grade A). These data are partly supported by observa-
tional studies stemming from registries which suggest 
that switching from one TNF inhibitor to another, as 
well as switching from TNF-blocking agents to ritux-
imab, is beneﬁ  cial.101–103 To date, the committee could 
not identify RCTs in which switching was appropriately 
compared between different biological agents and there-
fore a preference for a particular biological agent in this 
situation could not be established.104
(10) Azathioprine, ciclosporin A or cyclophosphamide—RA can 
run a course that is refractory to several DMARDs and 
biological agents and can be severely destructive and 
disabling.99 100 105 106 While in the previous recommenda-
tions four synthetic DMARDs and nine biological agents 
have been mentioned, allowing a variety of therapeutic 
options, refractoriness may and still will occur. In order 
to meet the needs of this group of patients, the task force 
has referred to agents for which the literature provides 
evidence on efﬁ  cacy. However, one needs to bear the 
toxicity in mind, especially in the case of ciclosporin A 
and cyclophosphamide; the latter drug should only be 
used in exceptional situations. A number of presumed 
DMARDs were excluded here, because the evidence 
for their efﬁ  cacy was deemed insufﬁ  cient; these include 
D-penicillamine, minocycline, auranoﬁ  n, tacrolimus and 
chlorambucil. With respect to antimalarial drugs we refer 
to the paragraph on recommendation 4.
(11) Intensive medication strategies—This statement supple-
ments several of the previous recommendations on drug 
treatment. Advocating intensive medication strategies 
refers to content of the strategy, such as MTX plus GCs 
or MTX plus biological agents, as well as tight monitor-
ing and rapid switching of treatments if treatment goals 
are not attained (benchmarking).12 107 The statement 
that patients with poor prognostic factors have more 
to gain ﬁ  nds its basis in the appreciation that patients 
with a favourable prognosis very often respond similarly 
to low-intensity monotherapy or intensive medication 
strategies,87 88 but that patients with a severe and aggres-
sive disease course often do not respond sufﬁ  ciently 
well to DMARD monotherapy or combination therapy 
without addition of GCs or biological agents.
(12) Tapering biological DMARDs—It is currently unclear how 
to continue or discontinue treatment in patients who 
have achieved remission. A thoroughly performed RCT 
on stopping synthetic DMARDs in patients in remission 
has shown that only about one-third of the patients who 
maintained their DMARDs ﬂ  ared as opposed to about 
two-thirds of those who stopped them108; moreover, 
remission was much harder to re-achieve after stopping 
DMARDs.109 This was also concluded in a recent meta-
analysis devoted to this issue.110 The ﬁ  rst aspect embed-
ded in this statement relates to the duration of remission: 
it should be persistent—that is, having lasted for several 
months, before tapering of synthetic and/or biologi-
cal DMARDs should be considered. However, before 
tapering DMARDs, GCs must have been tapered in line 
with statement No 6 and remission have persisted. The 
task force felt (by expert opinion) that biological agents 
could then be slowly tapered by expanding the interval 
between doses or reducing the dose, while synthetic 
DMARDs should be continued. No particular time frame 
was given here, since there are no data available; from an 
expert opinion’s view remission for at least 12 months 
might be regarded as ‘persistent’.110
(13) Tapering of synthetic DMARDs—This statement follows 
the preceding one, suggesting that tapering synthetic 
DMARD treatment in cases of longstanding remission 
could be considered after GCs and biological agents 
have been discontinued. Evidence supporting such an 
approach does not exist—neither details of a time frame 
nor dosing or interval duration during the tapering pro-
cess. Thus, the means of tapering is left to the discretion 
of patient and doctor. However, in light of the available 
data showing that stopping DMARDs is associated with 
an increased ﬂ  are frequency,108 110 the committee felt that 
tapering should be performed cautiously and assessed 
rigorously.
(14) Biological treatment in DMARD naïve patients While 
biological DMARDs, in line with statements Nos 7 and 
8, should, in general, be applied to patients for whom 
synthetic DMARD(s) have failed, the committee strongly 
felt that there are some patients for whom ﬁ  rst-line 
biological treatment combined with MTX has to be 
considered. Such patients will usually have unfavour-
able prognostic signs, including very active disease or 
early structural damage. Currently, only TNF inhibi-
tors are licensed for such patients, but other biological 
agents may receive similar approval with more trial data 
in the future. When evaluating results of trials using 
TNF inhibitors plus MTX in MTX naïve individuals 
and studies of the same compounds in patients with 
active disease despite MTX treatment,1 55 56 61 111–113 
patients naïve to MTX had higher response rates than 
MTX insufﬁ  cient responders, but many of the MTX-
naïve patients in the combination therapy arms would 
have responded to MTX monotherapy anyway. Thus, 
while, there is also additional evidence from strategic 
trials that employing TNF inhibitors plus MTX early 
is an effective treatment,36 49 more recent data suggest 
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that this approach may not be more effective in patients 
with early RA than starting synthetic DMARDs ﬁ  rst 
and adding a biological agent to the DMARD rapidly (in 
that study after 3 months) if active disease prevails.114 
However, hitherto no clinical trial has examined the 
actual expert-based recommendations to use such a 
strategy in few, selected patients as described above. 
Indeed, this statement received the lowest level of agree-
ment (8.0/10) and it was the only item for which a large 
number of rheumatologists stated that it was not their 
current practice and that this recommendation would 
change their practice.
(15) Adjustment of treatment—Prudence and knowledge will 
guide one to bear toxicity of agents and comorbidities 
in mind when prescribing drugs for RA. However, the 
rapidity of progression of joint damage, in addition to 
disease activity and other prognostic factors, may sup-
port decision-making in relation to statements Nos 7 
and 14, especially if joint damage appears to progress 
considerably despite the achievement of the desired 
treatment target; however, lag periods47 have to be taken 
into consideration before making such decision.
Economic aspects
The cost effectiveness of the therapeutic measures recom-
mended above has been assessed in detail by a dedicated 
SLR, which is also published separately.22 In sum, the avail-
able data suggest that all recommendations are known to be 
Figure 1  Algorithm based on the European League Against Rheumatism recommendations on rheumatoid arthritis management. DMARD, disease-
modifying antirheumatic drug; MTX, methotrexate; RF/ACPA, rheumatoid factor/anti-citrullinated peptide antibodies; TNF, tumour necrosis factor. *The 
treatment target is clinical remission or, if remission is unlikely to be achievable, at least low disease activity.
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cost effective with the exception of statement No 14 (table 3). 
However, an economic analysis considering only the excep-
tional patients considered in recommendation No 14 has not 
been performed. The committee does not preclude the possi-
bility that in this particular category of patients, the approach 
of starting biological agents as ﬁ  rst-line DMARD treatment 
may be cost effective.
Research agenda
Research questions have been formulated in all subgroups. 
These questions were assessed by the task force and the result 
of this discussion is summarised in table 4.
DISCUSSION
The task force has formulated 15 brief statements on the man-
agement of RA with synthetic and biological DMARDs. These 
statements were mostly based on a SLR with consensus ﬁ  nding 
on the wording of the recommendations, but partly also solely 
based on expert opinion. By this process and by stating the 
respective level of evidence and strength of recommendation for 
each item, the committee adhered to the EULAR standardised 
operating procedures for the development of recommenda-
tions.17 Moreover, where evidence was lacking and the task 
force had to arrive at an expert opinion, a research agenda was 
formulated to expedite the generation of evidence in the future.
The reasoning behind each statement and, particularly, 
behind the recommendations’ speciﬁ  c wordings is explained 
in detail in the results section and will not be repeated here. 
Importantly, the overall agreement with these statements, 
assessed anonymously several weeks after their formulation, 
was very high with means of ≥8/10 for all and >9/10 for seven 
of the 15 items (statements Nos 1–3, 8, 9, 11 and 15). The low-
est agreement (8/10) was received by the recommendation to 
start biological agents plus MTX as ﬁ  rst DMARD strategy in 
selected patients with very high disease activity and poor prog-
nostic markers (No 14). Indeed, it was also the only item where 
many rheumatologists stated that it was not their current prac-
tice and that this recommendation would change their current 
treatment practice (data not shown).
Dividing the task into ﬁ  ve speciﬁ  c areas may have helped 
unambiguous conclusions to be reached. Three of these areas 
were related to actual pharmacological treatment. Moreover, 
separating the SLRs on synthetic DMARDs into those with and 
those without addition of GCs facilitated the derivation of rec-
ommendations on combination therapy with a clarity that had 
previously been unappreciated; at the same time, this clarity 
raised new questions which require further elucidation.
It is worth noting that the task force felt that the best evi-
dence for efﬁ  cacy was available for four synthetic DMARDs 
(MTX, leﬂ  unomide, SSZ and parenteral gold; statements Nos 3 
and 4) and eight biological agents (adalimumab, certolizumab, 
etanercept, golimumab, inﬂ   iximab, abatacept, rituximab and 
tocilizumab; statements Nos 7–9). These 12 agents are also 
clearly stated in the itemised recommendation sentences. Two 
additional agents are mentioned in the text only—namely, anti-
malarial drugs and anakinra, because while effective in RA, their 
efﬁ  cacy is lower than that of other agents in their general class, 
synthetic or biological. A ﬁ  nal group of DMARDs is referred 
to as a last resort for patients for whom the above drugs have 
failed (statement No 10). It should be mentioned here that GCs 
also have disease-modifying ability,80 but the task force does 
not suggest using them as monotherapy owing to their adverse 
event proﬁ  le.81 Also, the readers are referred to the accompany-
ing papers on the SLRs for full information on the efﬁ  cacy of the 
respective agents.
The task force was convinced that modern treatment of RA 
should be goal oriented and governed by a strategic treatment 
approach. Remission or at the least low disease activity should 
be the therapeutic goal, in line with a recent recommendation on 
treatment goals in RA.48 115 On the way to attaining this target, 
patients should be closely monitored using composite disease 
Table 4 Research  agenda
  Research agenda
1 What is the efﬁ  cacy of GCs when added to DMARDs other than MTX 
or combinations of synthetic DMARDs with MTX, such as GC plus 
SSZ, compared with GC plus MTX and biological agents+MTX?
2 How comparable or different is the efﬁ  cacy of the various biological 
agents in patients with active disease despite MTX?
3 How comparable or different is the efﬁ  cacy of the various biological 
agents in patients who did not respond or lost response to TNF 
inhibitors?
4 Can biological agents be stopped in sustained remission with 
maintenance of remission, and how does stopping biological agents 
compare with stopping GC plus MTX or stopping GC?
5 What is the best way to taper treatment with synthetic and 
biological DMARDs in patients with longstanding remission? 
(comparison of different tapering ways)
6 Which differences will exist when comparing treatment strategies 
starting in parallel with MTX monotherapy plus GC, combination of 
synthetic DMARDs including MTX plus GC, combination of synthetic 
DMARDs including MTX without GC and biological agents plus MTX?
7 How big is the difference of clinical, functional, radiographic efﬁ  cacy 
when a treatment strategy aiming at remission by newly deﬁ  ned 
ACR/EULAR remission criteria is compared with a strategy aiming at 
achievement of low disease activity?
8 Can we ﬁ  nd predictors of response to synthetic DMARDs and 
different biological agents?
9 What is the effect of adding antimalarial drugs to MTX or to 
MTX+SSZ?
10 How cost effective is treating individuals with exceptionally high risk of 
rapid progression with biological agents versus synthetic DMARDs plus 
GCs when compared with using a sequence of agents as mandated by 
social security agencies or NICE?
This research agenda is partly based on recommendations derived by expert opinion for 
which sufﬁ  cient evidence is lacking.
ACR/EULAR, American College of Rheumatology/European League Against 
Rheumatism; DMARD, disease-modifying antirheumatic drug; GCs, glucocorticoids; 
MTX, methotrexate; NICE, National Institute of Health and Clinical Excellence; SSZ, 
sulfasalazine; TNF, tumour necrosis factor.
Table 3  Economic valuation of recommendations
Recommendation
Level of evidence and strength of 
recommendation for cost effectiveness
1N A
2 2c, B
3 2b, B
4 1b, 2b; B
5 2c, B
6 2c, B; 5, D
7 2b, B
8 2b, B
9 2b, B
10 NA
11 NA
12 2c, B
13 2c, B
14 1b, A (for being not cost effective*)
15 NA
*Not cost effective on the group level assessed in the respective studies, but not 
necessarily on the level of the exceptional individual patient as suggested in the 
recommendation.
NA, not applicable.
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activity measures116 117 and treatment adapted in accordance 
with the current recommendation if the treatment aim is not 
reached within preferably 3, but at most, 6 months.
The task force also felt strongly that, in general, DMARD 
treatment should be started with MTX at appropriately high 
doses, possibly with the addition of GCs for the short term, 
before other measures are taken if the therapeutic goal is not 
reached within a maximum of 6 months. The type of other 
measures should depend on prognostic factors: while biological 
agents may be considered in all patients after lack of achieve-
ment of remission or low disease activity on the above treat-
ment, such treatment is of more importance in the presence of 
poor prognostic factors, like the presence of autoantibodies, a 
high disease activity state or early erosive disease; it was felt 
quite appropriate to consider alternative synthetic DMARDs 
in the absence of poor prognostic factors. However, the task 
force also voiced its opinion that occasional patients with a par-
ticular need for rapid, highly effective intervention, may beneﬁ  t 
from starting a biological agent plus MTX as a viable and useful 
option.
Particular emphasis emerged upon analyses of combination 
therapies with synthetic DMARDs. The SLR did not reveal 
general superiority of such combinations in comparison with 
respective monotherapies. Only in studies where GCs were 
added to synthetic DMARD(s) (or were given in higher doses or 
more frequently than in controls) was there compelling evidence 
for superiority of such combinations, but notably, the superior-
ity was present regardless of whether GCs were added to syn-
thetic DMARD monotherapy (such as MTX) or to combinations 
of synthetic DMARDs (such as triple treatment with MTX, SSZ 
and antimalarial drugs).
GCs have a special place in the discussion (statements Nos 5, 
6, 8 and12). On the one hand, with respect to all outcomes, their 
efﬁ  cacy as monotherapy, but especially in combination with 
synthetic DMARDs is indisputable. On the other hand, their 
toxicity, particularly in the intermediate to long term, was con-
sidered to be signiﬁ  cant,82 so they should be used with caution 
and for only short periods of time. Tapering of GCs, but also 
of biological agents and eventually synthetic DMARDs, was an 
area of discussion too (statement No 13), but there is currently 
insufﬁ   cient evidence available about outcomes and potential 
risks and hence how to proceed in this regards. Therefore, the 
committee felt that tapering should only occur in cases of sus-
tained remission and should be part of the research agenda.
Figure 1 summarises the recommendations and the resulting 
algorithm. Phase I comprises the initiation of DMARD treat-
ment once RA has been diagnosed (statements Nos 1–6). Phase 
II deals with patients who did not achieve the treatment target 
with strategy I (statements Nos 7 and 8); here, patients are strati-
ﬁ  ed according to prognostic factors and this strategy contains 
the all steps until the use of the ﬁ  rst biological agent. Phase III 
relates to patients for whom the ﬁ  rst biological compound failed 
(statement No 9).
The recommendations on the management of RA provided 
here by the EULAR Task Force are not the ﬁ  rst of their kind. 
Indeed, EULAR has already published recommendations for 
early RA,115 but the present document relates to all patients with 
RA, rather than only those with early RA or undifferentiated 
arthritis and provides far more detail about pharmacological 
compounds. However, in line with the guidance document by 
Combe et al, the ﬁ  rst bullet point calls for a DMARD to be initi-
ated as soon as RA is diagnosed.
Aside from the EULAR document on early RA management, 
the ACR has provided therapeutic recommendations for several 
years.118 However, its most recent 2008 recommendations are 
complex and may not fully cover several aspects of drug treat-
ments and therapeutic strategies and goals.119 A comprehensive 
document published by the National Institute of Health and 
Clinical Excellence (NICE) of the UK29 at a time when our inves-
tigations were well advanced arrived at many conclusions that 
are supported by ours and vice versa, although the NICE pub-
lication does not consider biological treatments. Finally, many 
national rheumatological societies, such as the French or German 
societies, have published national guidance documents.
These EULAR recommendations have been developed by 
task force members from 12 European countries and the USA. 
They are meant to serve rheumatologists in Europe and else-
where, although we are aware that not all agents mentioned 
here are approved everywhere and, indeed, some agents had not 
yet been approved in Europe when we dealt with the respective 
literature, in the expectation that they would be licensed by the 
time this manuscript was submitted for publication.
Beyond rheumatologists, the document is also provided 
for patients with RA to inform them about current treatment 
goals, strategies and opportunities, as recognised through the 
important participation of patients in the task force. Finally, 
this document is also meant for ofﬁ  cials in governments, social 
security agencies and reimbursement agencies, since it provides 
the current state of thought in the area of RA management and 
is based on as much evidence as was available. In this regard, 
the economic valuation is also of signiﬁ  cance; indeed, all rec-
ommendations are supported by cost-effectiveness data, with 
the exception of starting biological agents before synthetic 
DMARDs; indeed, this conclusion is further supported by a 
recent Cochrane meta-analyis which stated that in patients 
with early RA. biological agents plus MTX may not differ sig-
niﬁ  cantly from placebo plus MTX with risk ratios of 1.43 and 
95% conﬁ  dence intervals of 0.98 to 2.09.120 However, in this 
regard more research is needed, since the recommendation only 
pertains to limited exceptional patients whose treatment has 
not yet been studied economically. Indeed, several of the rec-
ommendations are more strongly based on expert opinion and 
on clinical practice that has emerged in certain institutions than 
on available evidence. It is here where the opportunity to gar-
ner evidence has to meet or disprove expert opinion or practice 
and this is in part, the driver for the research agenda. Also, as 
has been the case over the past decade, new data on existing or 
new drugs or therapeutic strategies will emerge over the next 
few years. Therefore, we will carefully watch developments 
in the ﬁ  eld and assume that an amendment of these recom-
mendations may be needed in 2 years. Finally, irrespective of 
availability or affordability of certain agents, these recommen-
dations can also serve as a template for national societies which 
can adapt them to national clinical practices while remaining 
within their general framework.
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